(R)-ELX-02
(R)-ELX-02, also referred to as NB-124, is an eukaryotic ribosomal selective glycoside (ERSG) engineered to enhance read-through activity in patients with nonsense mutations, facilitating the generation of adequate levels of full-length functional protein.